Regeneron Pharmaceuticals, Inc.

Informe acción NasdaqGS:REGN

Capitalización de mercado: US$90.8b

Salud financiera de hoja de balance de Regeneron Pharmaceuticals

Salud financiera controles de criterios 5/6

Regeneron Pharmaceuticals has a total shareholder equity of $29.3B and total debt of $2.0B, which brings its debt-to-equity ratio to 6.8%. Its total assets and total liabilities are $37.4B and $8.1B respectively. Regeneron Pharmaceuticals's EBIT is $4.1B making its interest coverage ratio -6.7. It has cash and short-term investments of $9.8B.

Información clave

6.8%

Ratio deuda-patrimonio

US$1.98b

Deuda

Ratio de cobertura de intereses-6.7x
EfectivoUS$9.80b
PatrimonioUS$29.33b
Total pasivoUS$8.12b
Activos totalesUS$37.44b

Actualizaciones recientes sobre salud financiera

Recent updates

Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)

Nov 04

Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors

Sep 25

Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Sep 09
Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Regeneron Stock: Valuation Now Demands More Growth

Aug 26

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price

Aug 22
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price

Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Aug 04
Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Regeneron's Robust Pipeline And Financial Health Signal Continued Growth

Aug 02

Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings

Jul 11

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Jun 08
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

May 21
These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks

May 06

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Apr 30
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Apr 10
Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate

Mar 26

Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Feb 16
Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024

Feb 10

Regeneron's Push Into Obesity, Q4 2023 Earnings Review

Feb 02

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Jan 31
These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Análisis de la situación financiera

Pasivos a corto plazo: REGN's short term assets ($19.3B) exceed its short term liabilities ($3.7B).

Pasivo a largo plazo: REGN's short term assets ($19.3B) exceed its long term liabilities ($4.5B).


Historial y análisis de deuda-patrimonio

Nivel de deuda: REGN has more cash than its total debt.

Reducción de la deuda: REGN's debt to equity ratio has increased from 0% to 6.8% over the past 5 years.

Cobertura de la deuda: REGN's debt is well covered by operating cash flow (214.1%).

Cobertura de intereses: REGN earns more interest than it pays, so coverage of interest payments is not a concern.


Hoja de balance


Descubre empresas con salud financiera